Cannabis Science Appoints Former Walgreens Executive Pharmacist Dr. Moe Afaneh, Pharm D., MBA, NRCC, RNC as Chief Operating Officer (COO) To Immediately Bring the Cannabis Science Brand of Products to the National Market
DENVER, Feb 16, 2012 (BUSINESS WIRE) -- Cannabis Science, Inc. (OTCBB:CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to announce Dr. Moe Afaneh, Pharm D., MBA, NRCC, RNC has just been appointed as Chief Operations Officer for the company. Dr. Afaneh's first and immediate mandate is to bring the Cannabis Science product line to the national market through his personal expertise and industry relationships. Dr. Afaneh will serve as an asset to Cannabis Science by improving the overall efficiency and quality of its national pharmaceutical operations and penetrating new national markets.
Dr. Afaneh holds a Doctor of Pharmacy degree from Nova Southeastern University College of Pharmacy; he was accepted into the dual admission into the pharmacy program; entering college with 72 credits, and completed his doctorate in 6 years graduating at the top of his class, after which he received his MBA at Nova Southeastern University. Driven by a thirst for knowledge & determination to become a leader in the industry, to forge his mark in the medical community; he sought out to constantly gain more certifications & accreditation's; he became certified as an orthotic fitter, certified in providing vaccines, including Fluzone (the intra-nasal influenza vaccine), NIPCO certified in Osteoporosis, NIPCO certified in Long-Term Care & Hospice, NIPCO certified is Dyslipidemia and NPEC certified in chronic pain. His steps are similar to most great leaders seen in the early days of the pharmaceutical industry, those who are constantly innovating, adapting, and continuously working quality improvement.
Dr. Moe has received numerous awards and appointments in the Republican Party; Dr Moe Afaneh was appointed to the Presidential Commission for the City of Ft Lauderdale, and then was appointed the Florida delegate member of the House Republican Trust to the U.S. House of Representatives. Dr. Afaneh then went on to serve as a Founding Member of John Boehner to become Speaker of the House the National Republican Congressional Committee's prestigious Congressional Medal of Distinction. He also has received the Congressional Order of Merit. He continues to strive for excellence in his every endeavor to diligently serve the pharmaceutical marketing industry and is proud of one of his greatest accomplishments thus far, the co-founding of a biometric real-time monitoring system.
A prodigy in his twenties, Dr. Afaneh already has a decade of successful experience in pharmaceutical product marketing & branding and has extensive expertise compounding prescriptions; his compounding skills range from large farm animals to zoo animals and everything in between, including rare compounds for children that are very complex (i.e., pulmonary atrial hypertension in a 4-year-old child that required viagra lollipops to help treat his symptoms). Inspired through the mentality of eternal learning, gaining of knowledge, and refining skills, Dr. Afaneh has advanced as a leading resource in his field.
In his formative large corporation years Dr. Afaneh held executive responsibility with Walgreens as the youngest lead pharmacist in Florida. He was appointed to a 24 hour Walgreens Pharmacy that constantly ranked at the bottom of the district in all key point indicators. Driven by an unrelenting passion to not only improve the Pharmacy, but to become the top ranked pharmacy in not only his district but also all of South Florida. In that position he has lead the location from a dwindling revenues, averaging 221 prescriptions per day, gross sales of $322,408, with a net profit $ 101,843 (23%). Dr Moe Afaneh took an aggressive approach to turn the pharmacy around; he hired new staff, trained them, and delegated tasks to ensure there was a constant workflow that was organized. His organizational skills coupled with his constant mentoring and educating his staff, quickly began to turn the pharmacy around. The pharmacy began to run more efficiently, more organized, and the customer care was exceptional; all these lead to a huge influx in sales. The pharmacy began to grow at 35-42% month over month. Within 6 months the prescription count reached 645/day, sales soared to $966,789, with a net profit $282,765, this huge profit margin was due to maximizing new generic drugs, keeping payroll down, offering compounding to the 3 local hospitals and proper billing of insurance companies. After one year the prescription sales reached 875 rx/day, sales reached $1,245,678, net profit $389,754. Revenue for the year $14,789,900.
In addition to his accreditations, he has garnered a reputation of excellence and attributes with Walgreens; his success was accredited to his creativity, ambition, dedication to maintaining quality and constant revaluation of the business model.
Dr. Afaneh will be great asset as part of the company's growth plan, with his expertise in national pharmaceutical product development and marketing. Dr. Afaneh and his team are working with Cannabis Science to immediately enter the over-the-counter (OTC) market with Non-psychoactive Nutraceuticals, as well as the dispensary market in producing psychoactive and non-psychoactive cannabis based treatments. Cannabis Science is in the process of opening up shop in California, where Dr. Afaneh will oversee and manage, and eventually put these new delivery methods of cannabis treatments on the market to be retailed in the store.
Moe Afaneh, Pharm. D. held the position of chief executive officer of administration and marketing for A.I.P. Healthcare Services, a pharmacy that provides pharmaceuticals, specialized medical services and supplies, medication therapy management, and biometrics and counseling services In his capacity, Dr. Moe Afaneh was responsible for his first year sales of $7,566,900 at a net profit of 54%, year 2 gross sales reached $8,789,900 at a net profit of 62%, year gross sales reach $9,878,522 at a net profit of 67%. His constant innovative methods, networking, and working with other medical centers made him one of the most successful pharmacies in Florida. Daily overseeing operations, networking with members in the health care industry to promote synergetic growth, and using holistic approaches to meet patient needs; and having constant health fairs, health clinics, and working with the community
Dr. Moe Afaneh is also a certified orthotic fitter, and he holds official approval to practice as a certified pharmacist from the National Institute for Pharmacist Care Outcomes. Dr. Afaneh is a member of a number of industry-related organizations, which includes the Broward County Pharmacy Association, the Florida Pharmacy Association, Rx Pattern Analysis Tracking Robberies & Other Losses, and the American Pharmacists Association. He is also an affiliate of the Florida Business Leaders, the Republican Leadership Committee, the Reagan Congressional Commission and The National Science Board.
Dr. Moe Afaneh comments, "My motivation now is the incredible opportunity I have with the leaders of Cannabis Science. Cannabis Science and I share common motivation in our ability to explore new areas and constantly raising the bar on limitations. This is possible through Cannabis Science and their accomplishments in the Medical Cannabis Industry, especially with their focus on cancer. It's a bit of motivation mixed with a touch of passion to accomplishing things others have not that have a positive result for patients."
Given the progress the Medical Cannabis Industry has seen, Dr. Afaneh expects that prosperity is ahead as he continues with, "We didn't used to think that society is ready for Cannabis to go down the throat, now we see in great amounts of evidence that patients are ready for this and other solutions of absorption" He is preparing to mount a national public relations and marketing campaign that enlightens more people about the benefits of medical cannabis and present a viable option when mainstream medications fail to do the job.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
SOURCE: Cannabis Science, Inc.
CONTACT:
Cannabis Science Inc. Dr. Robert J. Melamede, 1-888-889-0888 President & CEO info@cannabisscience.com www.cannabisscience.com or Robert Kane, 1-561-234-6929 Investor Relations Management info@cannabisscience.com www.cannabisscience.com
Copyright Business Wire 2012
News 
Market Data 
Discover 
AI
